Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OccuLogix IPO Nursed By A Lot Of TLC; Proceeds Will Fund Eye Surgery Study

This article was originally published in The Gray Sheet

Executive Summary

OccuLogix, Inc. will seek a Medicare national coverage determination for itsRheo plasma pump-and-filter system to treat "dry" age-related macular degeneration (AMD) upon FDA approval

You may also be interested in...



OccuLogix RHEO

Firm reacquires its North American patent and trademark rights to non-ophthalmic indications for the therapeutic apheresis (TA) product from Rheogenx Biosciences March 29. In exchange, OccuLogix will provide marketing support to Rheogenx subsidiary PhereSys Therapeutics after RHEO's PMA garners FDA approval, expected by mid-2006, for the treatment of "dry" age-related macular degeneration (1"The Gray Sheet" Aug. 23, 2004, p. 8). PhereSys, which plans to become the preferred mobile TA provider of RHEO, also will receive special pricing for OccuLogix pumps and disposable treatment kits related to the device...

OccuLogix RHEO

Firm reacquires its North American patent and trademark rights to non-ophthalmic indications for the therapeutic apheresis (TA) product from Rheogenx Biosciences March 29. In exchange, OccuLogix will provide marketing support to Rheogenx subsidiary PhereSys Therapeutics after RHEO's PMA garners FDA approval, expected by mid-2006, for the treatment of "dry" age-related macular degeneration (1"The Gray Sheet" Aug. 23, 2004, p. 8). PhereSys, which plans to become the preferred mobile TA provider of RHEO, also will receive special pricing for OccuLogix pumps and disposable treatment kits related to the device...

OccuLogix Conducting Rheo Clinical Trial, Crossover Studies Simultaneously

FDA approval of two open-label, multi-center crossover studies of OccuLogix' Rheo therapy for "dry" age-related macular degeneration (AMD) will provide a first look of the device's long-term efficacy

Related Content

UsernamePublicRestriction

Register

MT020771

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel